Advanced Solid Tumours

Oncology
12
Pipeline Programs
8
Companies
23
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
6
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 9 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
4 programs
3
1
CeralasertibPhase 2Small Molecule1 trial
AZD1775Phase 15 trials
AdavosertibPhase 1Small Molecule4 trials
CeralasertibPhase 1Small Molecule1 trial
Active Trials
NCT04462952Completed6Est. Sep 2021
NCT03313557Completed48Est. May 2019
NCT03028766Completed9Est. Feb 2021
+8 more trials
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
1
1
WX-554Phase 1/21 trial
WX-037Phase 11 trial
Active Trials
NCT01859351Terminated13Est. Apr 2014
NCT01581060Terminated41Est. Apr 2014
Bicycle Therapeutics
Bicycle TherapeuticsMA - Cambridge
1 program
1
BT1718Phase 1/21 trial
Active Trials
NCT03486730Completed72Est. Nov 2023
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
1
Durvalumab + Tremelimumab + metronomic VinorelbinePhase 1/2
Philogen
PhilogenItaly - Monteriggioni
1 program
1
L19IL2Phase 1/21 trial
Active Trials
NCT01058538Completed33Est. Nov 2009
LaNova Medicines
LaNova MedicinesChina - Shanghai
1 program
1
LM-168Phase 1/21 trial
Active Trials
NCT06868199RecruitingEst. Feb 2028
Pyxis Oncology
Pyxis OncologyBOSTON, MA
1 program
1
PYX-201Phase 1/21 trial
Active Trials
NCT06795412Recruiting220Est. Dec 2027
Fusion Pharmaceuticals Inc.
1 program
1
[111In]-FPI-1547 InjectionPhase 11 trial
Active Trials
NCT03746431Terminated78Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AstraZenecaCeralasertib
AstraZenecaAdavosertib
AstraZenecaAZD1775
AstraZenecaAZD1775
LaNova MedicinesLM-168
Pyxis OncologyPYX-201
Bicycle TherapeuticsBT1718
Heidelberg PharmaWX-554
PhilogenL19IL2
AstraZenecaCeralasertib
AstraZenecaAdavosertib
AstraZenecaAdavosertib
AstraZenecaAdavosertib
AstraZenecaAZD1775
Fusion Pharmaceuticals Inc.[111In]-FPI-1547 Injection

Showing 15 of 23 trials with date data

Clinical Trials (23)

Total enrollment: 956 patients across 23 trials

NCT04564027AstraZenecaCeralasertib

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Start: Dec 2020Est. completion: Feb 202554 patients
Phase 2Completed
NCT04590248AstraZenecaAdavosertib

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma

Start: Nov 2020Est. completion: Feb 2023109 patients
Phase 2Completed
NCT02087241AstraZenecaAZD1775

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Start: Mar 2014Est. completion: Jun 201522 patients
Phase 2Terminated
NCT02087176AstraZenecaAZD1775

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Start: Mar 2014Est. completion: May 201548 patients
Phase 2Terminated
NCT06868199LaNova MedicinesLM-168

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Start: May 2025Est. completion: Feb 2028
Phase 1/2Recruiting
NCT06795412Pyxis OncologyPYX-201

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Start: Apr 2025Est. completion: Dec 2027220 patients
Phase 1/2Recruiting
NCT03486730Bicycle TherapeuticsBT1718

BT1718 in Patients with Advanced Solid Tumours.

Start: Jan 2018Est. completion: Nov 202372 patients
Phase 1/2Completed
NCT01581060Heidelberg PharmaWX-554

Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours

Start: Mar 2012Est. completion: Apr 201441 patients
Phase 1/2Terminated
NCT01058538PhilogenL19IL2

A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

Start: Nov 2005Est. completion: Nov 200933 patients
Phase 1/2Completed
NCT06929260AstraZenecaCeralasertib

A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z

Start: May 2025Est. completion: Dec 20251 patients
Phase 1Terminated
NCT05008913AstraZenecaAdavosertib

Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib

Start: Oct 2021Est. completion: Nov 20212 patients
Phase 1Terminated
NCT04949425AstraZenecaAdavosertib

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Start: Sep 2021Est. completion: Apr 20223 patients
Phase 1Terminated
NCT04959266AstraZenecaAdavosertib

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

Start: Jun 2021Est. completion: Jun 20225 patients
Phase 1Terminated
NCT04462952AstraZenecaAZD1775

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Start: Jun 2020Est. completion: Sep 20216 patients
Phase 1Completed
NCT03746431Fusion Pharmaceuticals Inc.[111In]-FPI-1547 Injection

A Phase 1 Study of [225Ac]-FPI-1434 Injection

Start: Jan 2019Est. completion: Dec 202578 patients
Phase 1Terminated
NCT03313557AstraZenecaAZD1775

AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

Start: Oct 2017Est. completion: May 201948 patients
Phase 1Completed
NCT03028766AstraZenecaAZD1775

WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer

Start: Jun 2017Est. completion: Feb 20219 patients
Phase 1Completed
NCT02906059AstraZenecaAZD1775

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Start: Sep 2016Est. completion: Mar 20207 patients
Phase 1Completed
NCT02610075AstraZenecaAZD1775

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Start: Dec 2015Est. completion: Apr 201862 patients
Phase 1Completed
NCT02585973AstraZenecaAZD1775

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Start: Oct 2015Est. completion: Jun 202112 patients
Phase 1Completed
NCT02482311AstraZenecaAZD1775

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Start: Jul 2015Est. completion: Aug 201992 patients
Phase 1Completed
NCT02341456AstraZenecaAZD1775

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

Start: Jan 2015Est. completion: Jul 201819 patients
Phase 1Completed
NCT01859351Heidelberg PharmaWX-037

Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours

Start: Jul 2013Est. completion: Apr 201413 patients
Phase 1Terminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4h ago

Office Administrator

SystImmune
4h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
4h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
4h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
4h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 956 patients
8 companies competing in this space

Related Indications

Breast Cancer(577)Prostate Cancer(385)Non-small Cell Lung Cancer(378)Multiple Myeloma(359)Cancer(249)Advanced Solid Tumors(226)Acute Myeloid Leukemia(209)Neoplasms(199)Colorectal Cancer(171)Melanoma(170)